Research Papers:

Indomethacin-based stimuli-responsive micelles combined with paclitaxel to overcome multidrug resistance

Shuanghu Wang, Xueying Tan, Shujuan Li, Yunfang Zhou, Peiwu Geng, Ailian Hua, Aiping Deng and Zhihong Yu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:111281-111294. https://doi.org/10.18632/oncotarget.22781

Metrics: PDF 1767 views  |   HTML 1903 views  |   ?  


Shuanghu Wang1,*, Xueying Tan2,*, Shujuan Li2, Yunfang Zhou1, Peiwu Geng1, Ailian Hua1, Aiping Deng3 and Zhihong Yu3

1The Laboratory of Clinical Pharmacy, The Sixth Affiliated Hospital of Wenzhou Medical University, The People's Hospital of Lishui, Lishui 323000, China

2College of Pharmacy, Zhejiang Pharmaceutical College, Ningbo 315000, China

3Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China

*These authors have contributed equally to this work

Correspondence to:

Zhihong Yu, email: [email protected]

Keywords: breast cancer; multidrug resistance; paclitaxel; indomethacin; drug delivery system

Received: June 06, 2017     Accepted: November 19, 2017     Published: November 30, 2017


Development of multidrug resistance against antitumor agents is a major limiting factor for the successful chemotherapy. Currently, both amphiphilic polymeric micelles and chemosensitizers have been proposed to overcome MDR during chemotherapy. Herein, the redox-responsive polymeric micelles composed of dextran and indomethacin (as chemosensitizer) using a disulfide bond as the linker are prepared (DEX-SS-IND) for delivery of antitumor agent paclitaxel (PTX). The high level of glutathione in tumor cells selectively breaks the disulfide bond, leading to the rapid breakdown and deformation of redox-responsive polymeric micelles. The data show that DEX-SS-IND can spontaneously form the stable micelles with high loading content (9.48 ± 0.41%), a favorable size of 45 nm with a narrow polydispersity (0.157), good stability, and glutathione-triggered drug release behavior due to the rapid breakdown of disulfide bond between DEX and IND. In vitro antitumor assay shows DEX-SS-IND/PTX micelles effectively inhibit the proliferation of PTX-resistant breast cancer (MCF-7/PTX) cells. More impressively, DEX-SS-IND/PTX micelles possess the improved plasma pharmacokinetics, enhanced antitumor efficacy on tumor growth in the xenograft models of MCF-7/PTX cells, and better in vivo safety. Overall, DEX-SS-IND/PTX micelles display a great potential for cancer treatment, especially for multidrug resistance tumors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22781